Soluble Suppression of Tumorigenicity 2 is Directly Correlated with Glycated Hemoglobin in Individuals with an Average glycemia in the Normal/Prediabetes Range

References

• Lohning M, Grogan JL, Coyle AJ, et al. T1/ST2 expression is enhanced on CD4+ T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo. J Immunol. 1999;162:3882–3889.
   PubMed Web of Science ®Google Scholar
• Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007;282:26369–26380. doi:10.1074/jbc.M704916200
   PubMed Web of Science ®Google Scholar
• Mehraj V, Jenabian MA, Ponte R, et al. The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. AIDS. 2016;30:1617–1627. doi:10.1097/QAD.0000000000001105
   PubMed Web of Science ®Google Scholar
• Miller AM, Asquith DL, Hueber AJ, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107:650–658. doi:10.1161/CIRCRESAHA.110.218867
   PubMed Web of Science ®Google Scholar
• Miller AM, Liew FY. The IL-33/ST2 pathway–A new therapeutic target in cardiovascular disease. Pharmacol Ther. 2011;131:179–186. doi:10.1016/j.pharmthera.2011.02.005
   PubMed Web of Science ®Google Scholar
• Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008;205:339–346. doi:10.1084/jem.20071868
   PubMed Web of Science ®Google Scholar
• Hasan A, Al-Ghimlas F, Warsame S, et al. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol. 2014;15:19. doi:10.1186/1471-2172-15-19
   PubMed Web of Science ®Google Scholar
• Anand G, Vasanthakumar R, Mohan V, Babu S, Aravindhan V. Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134). Int J Clin Exp Pathol. 2014;7:8008–8015.
   PubMedGoogle Scholar
• Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–1549. doi:10.1172/JCI30634
   PubMed Web of Science ®Google Scholar
• McLaren JE, Michael DR, Salter RC, et al. IL-33 reduces macrophage foam cell formation. J Immunol. 2010;185:1222–1229. doi:10.4049/jimmunol.1000520
   PubMed Web of Science ®Google Scholar
• Lusis AJ. Atherosclerosis. Nature. 2000;407:233–241. doi:10.1038/35025203
   PubMed Web of Science ®Google Scholar
• Pawlak K, Mysliwiec M, Pawlak D. Oxidized LDL to autoantibodies against oxLDL ratio - The new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis. 2012;224:252–257. doi:10.1016/j.atherosclerosis.2012.07.011
   PubMed Web of Science ®Google Scholar
• Zhao XY, Zhou L, Chen Z, et al. The obesity-induced adipokine sST2 exacerbates adipose treg and ILC2 depletion and promotes insulin resistance. Sci Adv. 2020;6:eaay6191. doi:10.1126/sciadv.aay6191
   PubMed Web of Science ®Google Scholar
• Fousteris E, Melidonis A, Panoutsopoulos G, et al. Toll/interleukin-1 receptor member ST2 exhibits higher soluble levels in type 2 diabetes, especially when accompanied with left ventricular diastolic dysfunction. Cardiovasc Diabetol. 2011;10:101. doi:10.1186/1475-2840-10-101
   PubMedGoogle Scholar
• Lin YH, Zhang RC, Hou LB, et al. Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. Diabetes Res Clin Pract. 2016;118:140–145. doi:10.1016/j.diabres.2016.06.006
   PubMed Web of Science ®Google Scholar
• Hu X, Zhang H, Song Y, et al. Soluble ST2 is associated with increased carotid intima-media thickness in patients with type 2 diabetes mellitus: a case-control study. Medicine. 2020;99:e18940. doi:10.1097/MD.0000000000018940
   PubMedGoogle Scholar
• Griffith ML, Jagasia MH, Misfeldt AA, et al. Pretransplantation C-peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:86–92. doi:10.1016/j.bbmt.2010.06.010
   PubMedGoogle Scholar
• Rowan CM, Teagarden AM, Cater DT, Moser EAS, Baykoyannis G, Paczesny S. Early high plasma ST2, the decoy IL-33 receptor, in children undergoing hematopoietic cell transplantation is associated with the development of post-transplant diabetes mellitus. Haematologica. 2020;105:e249–e252. doi:10.3324/haematol.2019.222992
   PubMedGoogle Scholar
• Sharim J, Daniels LB. Soluble ST2 and soluble markers of fibrosis: emerging roles for prognosis and guiding therapy. Curr Cardiol Rep. 2020;22:41. doi:10.1007/s11886-020-01288-z
   PubMedGoogle Scholar
• Dzudie A, Dzekem BS, Kengne AP. NT-pro BNP and plasma-soluble ST2 as promising biomarkers for hypertension, hypertensive heart disease and heart failure in sub-Saharan Africa. Cardiovasc J Afr. 2017;28:406–407.
   PubMedGoogle Scholar
• Cardellini M, Rizza S, Casagrande V, et al. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects. Acta Diabetol. 2019;56:273–280. doi:10.1007/s00592-018-1230-z
   PubMedGoogle Scholar
• Somuncu MU, Kalayci B, Avci A, et al. Predicting long-term cardiovascular outcomes of patients with acute myocardial infarction using soluble ST2. Horm Mol Biol Clin Investig. 2020. doi:10.1515/hmbci-2019-0062
   PubMedGoogle Scholar
• Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A. 2010;107:8017–8022. doi:10.1073/pnas.0912678107
   PubMed Web of Science ®Google Scholar
• Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 2004;30:1468–1473. doi:10.1007/s00134-004-2184-x
   PubMed Web of Science ®Google Scholar
• Hodzic Z, Schill EM, Bolock AM, Good M. IL-33 and the intestine: the good, the bad, and the inflammatory. Cytokine. 2017;100:1–10. doi:10.1016/j.cyto.2017.06.017
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors C, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 375;2010:2215–2222. doi:10.1016/S0140-6736(10)60484-9
   PubMed Web of Science ®Google Scholar
• Gao Y, Lu B, Sun ML, et al. Comparison of atherosclerotic plaque by computed tomography angiography in patients with and without diabetes mellitus and with known or suspected coronary artery disease. Am J Cardiol. 2011;108:809–813. doi:10.1016/j.amjcard.2011.04.032
   PubMed Web of Science ®Google Scholar
• Reis JP, Allen NB, Bancks MP, et al. Duration of diabetes and prediabetes during adulthood and subclinical atherosclerosis and cardiac dysfunction in middle age: the CARDIA study. Diabetes Care. 2018;41:731–738. doi:10.2337/dc17-2233
   PubMedGoogle Scholar
• Marathe PH, Gao HX, Close KL. American Diabetes Association standards of medical care in diabetes 2017. J Diabetes. 2017;9:320–324. doi:10.1111/1753-0407.12524
   PubMed Web of Science ®Google Scholar
• Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54:254–260. doi:10.1210/jcem-54-2-254
   PubMed Web of Science ®Google Scholar
• Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81:555–563. doi:10.1093/ajcn/81.3.555
   PubMed Web of Science ®Google Scholar
• Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460–468. doi:10.1016/0002-9149(94)90676-9
   PubMed Web of Science ®Google Scholar
• Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Diabetologia. 2012;55:273–278. doi:10.1007/s00125-011-2387-y
   PubMed Web of Science ®Google Scholar
• Faraj TA, McLaughlin CL, Erridge C. Host defenses against metabolic endotoxaemia and their impact on lipopolysaccharide detection. Int Rev Immunol. 2017;36:125–144. doi:10.1080/08830185.2017.1280483
   PubMed Web of Science ®Google Scholar
• Mildner M, Storka A, Lichtenauer M, et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res. 2010;87:769–777. doi:10.1093/cvr/cvq104
   PubMed Web of Science ®Google Scholar
• Brint EK, Xu D, Liu H, et al. ST2 is an inhibitor of interleukin 1 receptor and toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol. 2004;5:373–379. doi:10.1038/ni1050
   PubMed Web of Science ®Google Scholar
• Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol. 2009;183:1446–1455. doi:10.4049/jimmunol.0803067
   PubMed Web of Science ®Google Scholar
• Villacorta H, Maisel AS. Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol. 2016;106:145–152. doi:10.5935/abc.20150151
   PubMed Web of Science ®Google Scholar
• Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008;52:2166–2174. doi:10.1016/j.jacc.2008.09.027
   PubMed Web of Science ®Google Scholar